VCYT Veracyte, Inc. | US92337F1075
Company Profile
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
Latest News
Earnings Preview: Veracyte (VCYT) Q2 Earnings Expected to Decline
Zacks • 07/23/2026
Earnings Calendar and Analysis for This Week (July 27-31)
Kiplinger • 07/24/2026
Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?
Motley Fool • 07/23/2026
Which Healthcare ETF Is the Better Buy: iShares' Global IXJ or First Trust's Biotech FBT?
Motley Fool • 07/21/2026
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Website | https://www.veracyte.com |
| Audit Risk | 2 |
| Board Risk | 2 |
| Overall Risk | 3 |
| Market Cap | 4.52B |
| Trailing P/E | 52.42 |
| Forward P/E | 30 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | 1.08 |
| Forward EPS | 1.89 |
| Book Value | 16.5 |
| Price-to-Book | 3.43 |
| Enterprise-to-Revenue | 7.6 |
| Enterprise-to-EBITDA | 39.51 |
| Short Ratio | 4.77 |
| Earnings Date | 07/30/2026 |
| Earnings Call Date | 07/30/2026 |
| Earnings Average | 0.43 |
| Earnings Low | 0.4 |
| Earnings High | 0.47 |
| Revenue Average | 144.48M |
| Revenue Low | 142.90M |
| Revenue High | 147.90M |